等待開盤 10-08 09:30:00 美东时间
0.000
0.00%
Tempus AI (TEM) announced on Wednesday that it expanded its multi-year deal with Moderna (MRNA) and Merck & Co. (MRK) to support the potential commercialization of intismeran autogene, an individualiz...
10-07 21:01
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Mark Delaney downgraded Gentex Corp (NASDAQ:GNTX) from Neutral to Sell and ...
10-06 21:12
BTIG analyst Mark Massaro downgrades Personalis (NASDAQ:PSNL) from Buy to Neutral.
10-06 18:02
高盛给予Tempus AI“中性”评级和75美元目标价;xT与xF报销红利可期,但大药企合同和护城河持久性仍待验证。
09-22 21:12
An announcement from 4basebio UK Societas ( ($GB:4BB) ) is now available. 4base...
09-07 14:19
Biotech could be entering a broader re-rating as artificial intelligence and genomics accelerate drug discovery, while health care valuations remain at a significant discount to the broader market, according to David Song, MD, Ph.D., CFA and investment partner at Tema ETFs. "Biotech is already in th...
09-04 06:14
Piper Sandler upgraded Tempus AI (TEM) to Overweight from Neutral and raised its price target to $76 from $56 per share on Tuesday, noting three key growth drivers in the AI-driven diagnostics company...
09-01 23:49
Pennsylvania has become the first state to record fatalities linked to measles this year after two unvaccinated individuals died of the infectious viral disease, the state’s health department said on ...
08-26 01:22
Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week. Personalis Deal Draws Attention The recent surge in the stock was driven by momentum from Phase 3 INTerpath-001 results from Merck & Co. Inc. (NYSE:MRK) and Mo...
08-25 02:02
• Tempus AI shares declined due to profit-taking despite receiving FDA clearance. • Technical overextension and insider share sales exacerbated the stock price retracement. • The company reported $1.27B annual revenue and a net loss of $-245.03M.
08-24 17:15